An observational study in Pulmonary Embolism (Diagnosis), sponsored by Dr. Kerstin de Wit. Completed at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-12.
Sponsored by Dr. Kerstin de Wit · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 74 studies in Pulmonary Embolism with a site in Canada — 7 open to participants now, 9 under way, 3 of them phase 3. Pulmonary Embolism · Canada.
Among the 74 studies in Pulmonary Embolism with a site in Canada, this one is the 15th largest by enrollment of the 20 observational ones that give a count, is one of 4 that started in 2023, is one of 20 observational ones, and was the 68th registered.
833 studies on the registry are indexed under Pulmonary Embolism; 172 are open to participants now.
Browse Pulmonary Embolism studies →7 of the 74 studies in Pulmonary Embolism with a site in Canada are open now. Recruiting first, the newest first:
University of Calgary · Sites in Canada, Belgium, Denmark and 4 more countries
Ages 18+ · Women only
Regeneron Pharmaceuticals · Sites in Canada, United States
Ages 18+
Dr. Kerstin de Wit · Sites in Canada
Ages 18+
Jewish General Hospital · Sites in Canada
Ages 18–75
McMaster University · Sites in Canada
Ages 18+ · Healthy volunteers
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 130 Pulmonary Embolism studies recruiting now, 110 (85%) set no upper age limit and 5 (4%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
74 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 7 · Phase 3 26 · Phase 4 4
First in 1998; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 200 is below the median of 361 across 366 observational studies indexed under Pulmonary Embolism.
Median enrollment 850 across the 53 interventional studies, 612 across the 20 observational. Of the 57 that completed or were terminated, 15 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 74 have an industry lead sponsor. The 10 most frequent:
Dr. Kerstin de Wit is the lead sponsor of 6 studies on the registry; 4 are open to participants now.
Dr. Kerstin de Wit has 2 studies filed under Pulmonary Embolism — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 74 studies in Pulmonary Embolism with a site in Canada, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of this pilot study is to assess the feasibility of a larger study to determine the Adjust-Unlikely algorithm safety and efficiency for diagnosing PE.
The pilot study objectives are to:
The pilot study hypothesis is that the investigators can recruit at least 20 patients per month and successfully follow at least 90% of patients for 90 days.
Patients presenting to emergency departments and urgent care centres with symptoms of PE.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The proportion of patients who have PE excluded by the Adjust-Unlikely algorithm and who are subsequently diagnosed with either PE or lower limb DVT.
Time frame: 90 days following index presentation
Plan to share: No
No publications or documents are linked to this record.
Ran from Apr 2023 to primary completion in Sep 2023, 4 months.
Of 135 non-industry observational studies under Pulmonary Embolism, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 119. This study's 4 months is below that.
Counting every sponsor, half of 160 studies reached it within 47 months; a quarter within 21 and three quarters within 105.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dr. Kerstin de Wit